Summary
The pharmacokinetics of digoxin and metildigoxin were investigated in geriatric patients on maintenance treatment. Minimum serum glycoside concentrations were determined on 3 consecutive days, and the elimination rate over a withdrawal period of 4 to 6 days was studied.
In patients with serum creatinine levels of ≤1.3mg/dl, the oral standard dose (D1) of digoxin necessary for a minimum serum concentration of 1.0ng/ml was 1.4 times higher than that of metildigoxin. There was no significant difference in the elimination rate of both glycosides.
The pharmacokinetics of metildigoxin were further investigated in patients with elevated serum creatinine levels. The standard dose was best correlated with the creatinine clearance, calculated from the serum creatinine, age, weight and sex of the patients. The apparent volume of distribution of metildigoxin decreased with the drug’s total body clearance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson, K.-E.; Johansson, B.W.; Ledermann, H.; van Schenck, H. and Thorell, J.I.: The effects of digoxin and β-methyldigoxin on the heart rate of decompensated patients with atrial fibrillation. European Journal of Clinical Investigation 7: 3–6 (1977).
Bartels, H. and Böhmer, M.: Eine Mikromethode zur Kreatinin-bestimmung. Clinica Chimica Acta 32: 81–85 (1971).
Coburn, P.; Kongola, G.M.W. and Mawer, G.E.: Comparison of medigoxin and digoxin in the control of atrial fibrillation. British Journal of Clinical Pharmacology 8: 53–58 (1979).
Cockcroft, D.W. and Gault, M.H.: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41 (1976).
Gault, M.H.; Jeffrey, J.R.; Chirito, E. and Ward, L.L.: Studies of digoxin dosage, kinetics and serum concentrations in renal failure and review of the literature. Nephron 17: 161–187 (1976).
Hayward, R.P.; Greenwood, H. and Hamer, J.: Comparison of digoxin and medigoxin in normal subjects. British Journal of Clinical Pharmacology 6: 81–86 (1978).
Hinderling, P.H.; Garrett, E.R. and Wester, R.C.: Pharmacokinetics of β-methyldigoxin in healthy humans II: Oral studies and bioavailability. Journal of Pharmaceutical Sciences 66: 314–325 (1977).
Iisalo, E.: Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 2: 1–16 (1977).
Jelliffe, R.W. and Brooker, G.: A nomogram for digoxin therapy. American Journal of Medicine 57: 63–68 (1974).
Keller, F.; Blumenthal, H.P.; Maertin, K. and Rietbrock, N.: Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and β-methyldigoxin. European Journal of Clinical Pharmacology 12: 387–392 (1977).
Kramer, P.: Digitalis-Pharmacokinetik und -Therapie bei gestörter Nierenfunktion. Klinische Wochenschrift 55: 1–11 (1977).
Larbig, D.: Herzinsuffizienz: Digitalistherapie. Therapiewoche 25: 48–61 (1975).
Larbig, D. and Haasis, R.: Radioimmunchemische Bestimmungen der Konzentration von Digoxin und Digoxin-Derivaten. Digitalistherapie — Beiträge zur Pharmakologie u. Klinik, pp.62–75 (Springer-Verlag, Berlin, Heidelberg, New York 1975).
Marinow, J.; Olcay, A.; Schaumann, W. and Weiss, W.: Serum glycoside concentrations after single or repeated intravenous doses of β-methyl-digoxin and digoxin. European Journal of Clinical Pharmacology 11: 213–218 (1977).
Ochs, H.R.; Greenblatt, D.J.; Bodem, G. and Harmatz, J.S.: Dose-independent pharmacokinetics of digoxin in humans. American Heart Journal 4: 507–511 (1978).
Ohnhaus, E.E.; Spring, P. and Dettli, L.: Eliminationskinetik und Dosierung von Digoxin bei Patienten mit Niereninsuffizienz. Deutsche Medizinische Wochenschrift 99: 1797–1803 (1974).
Redfors, A.: Plasma digoxin concentration — its relation to digoxin dosage and clinical effects in patients with atrial fibrillation. British Heart Journal 34: 383–391 (1972).
Rennekamp, H.; Rennekamp, Ch.; Abshagen, U.; van Bergmann, K. and Rietbrock, N.: Pharmacokinetic behaviour of 4′″-methyl-digoxin in man. Naunyn-Schmiedeberg’s Archives of Pharmacology 273: 172–174 (1972).
Rietbrock, N.; Oeff, F.; Maertin, K. and Kuhlmann, J.: Glykosidkonzentrationen im Plasma und Intoxikationshäufigkeit nach β-Methyldigoxin und β-Acetyldigoxin unter standardisierten Bedingungen. Herz/Kreislauf 10: 267–273 (1978).
Schaumann, W. and Kaufmann, B.: Résorption, distribution et élimination des glucosides digitaliques. Actualités Pharmacologiques 31: 143–168 (1979).
Schaumann, W. and Kaufmann, B.: Explanation of the error in calculating the distribution volume using a two-compartment model. Clinical Pharmacology, Therapy and Toxicology. In press (1981).
Schaumann, W.; Glocke, M. and Kaufmann, B.: Berechnung der voraussichtlichen Erhaltungsdosen von Metildigoxin und Digoxin aus Geschlecht, Körpergewicht, Alter und Serum-Creatinin. Herz Kreislauf 13: 349–358 (1981).
Twittenhoff, W.T.; Strauch, M.; Kütemeyer, M.; Koch, K. and Schaumann, W.: Extrarenal clearance, distribution volume and elimination rate of digoxin and metildigoxin in anuric patients. Clinical Pharmacology, Therapy and Toxicology. In press (1981).
Weiss, W.; Olcay, A.; Teufel, W. and Glocke, M.: Vergleichende Untersuchungen der Glykosid-Konzentration im Serum bei Erhaltungstherapie mit Lanicor®, Card-Lamuran®, MF 708 d und Lanitop®. Medizinische Klinik 70: 1367–1374 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaufmann, B., Olcay, A., Schaumann, W. et al. Pharmacokinetics of Metildigoxin and Digoxin in Geriatric Patients with Normal and Elevated Serum Creatinine Levels. Clin Pharmacokinet 6, 463–468 (1981). https://doi.org/10.2165/00003088-198106060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198106060-00004